Successful Employment of Brentuximab Vedotin in a Patient Undergoing Hemodialysis: The First Real-life Experience
Brentuximab vedotin (BV), an anti-CD30-specific antibody-drug conjugate (ADC), is one of the most promising new agents employed in the treatment of peripheral T-cell lymphomas (PTCLs), in particular, systemic anaplastic large cell lymphomas (sALCL).1,2 The drug has proved to be safe and effective both as a single agent in relapsed/refractory disease and in combination with standard chemotherapy in the first-line setting.3-7
Publication date: Available online 8 October 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Hayder Saeed, Lubomir Sokol
Publication date: Available online 5 October 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Leyla Bojanini, Liuyan Jiang, Alexander J. Tun, Ernesto Ayala, David M. Menke, Bradford Hoppe, Mohamed A. Kharfan-Dabaja, Han W. Tun, Muhamad Alhaj Moustafa
Publication date: Available online 18 September 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Pierluigi Porcu, Stacie Hudgens, Steven Horwitz, Pietro Quaglino, Richard Cowan, Larisa Geskin, Marie Beylot-Barry, Lysbeth Floden, Martine Bagot, Athanasios Tsianakas, Alison Moskowitz, Auris Huen, Brigitte Dreno, Stéphane Dalle, Dolores Caballero, Mollie Leoni, Stephen Dale, Fiona Herr, Madeleine Duvic
Publication date: September 2020Source: Clinical Lymphoma Myeloma and Leukemia, Volume 20, Issue 9Author(s): Eric C. Vonderheid, Jennifer Jakubowski, J. Steve Hou
Publication date: Available online 22 July 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Satoshi Ichikawa, Noriko Fukuhara, Kei Saito, Eijiro Furukawa, Koichi Onodera, Yasushi Onishi, Hisayuki Yokoyama, Ryo Ichinohasama, Hideo Harigae
Publication date: Available online 22 July 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Anne Shah, Allison Petrilla, Mayvis Rebeira, Joseph Feliciano, Julie Lisano, Thomas W. LeBlanc
Publication date: Available online 30 June 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Matthew R. Kudelka, Jeffrey M. Switchenko, Mary Jo Lechowicz, Natia Esiashvili, Christopher R. Flowers, Mohammad K. Khan, Pamela B. Allen
This was a prescription claims-based analysis of the real-world treatment patterns, health care resource utilization, costs and survival outcomes in 2551 Medicare beneficiaries newly diagnosed with PTCL from 2011-2017. Data indicate significant use of resources prior to and following diagnosis, with no evident standard of care; survival outcomes at the time of analysis remained poor.
Angioimmunoblastic T-cell lymphoma (AITL) is a relatively rare but distinct histological subtype of peripheral T-cell lymphoma (PTCL), with a follicular helper T-cell origin, and is characterized by systemic symptoms, generalized lymphadenopathy, and hepatosplenomegaly.1 Pathologically, the neoplastic cells in AITL are present in a polymorphous inflammatory background. Irregular proliferation of follicular dendritic cells and proliferative high endothelial venules are also characteristic of AITL.
In this study, we found that CaMKIIγ was aberrantly activated in human MM and its expression level was positively correlated with malignant progression and poor prognosis. Ectopic expression of CaMKIIγ promoted cell growth, colony formation, cell cycle progress and inhibited apoptosis of MM cell lines, whereas, knockdown of CAMKIIγ expression suppressed MM cell growth in vitro and in vivo. Mechanically, we observed that CaMKIIγ overexpression upregulated p-ERK and p-Stat3 levels and suppression of CaMKIIγ had opposite effects. CaMKIIγ is frequently dysregulated in MM and plays a critical...